Resistance Training Preserves Muscle During Tirzepatide Use

Lifting weights three times a week while taking tirzepatide helps adults with obesity preserve muscle mass and increase strength, according to a University of Western Australia study published November 9 in Nature Medicine.

The 40-week trial evaluated 120 adults with obesity or overweight and a related health condition. Participants were divided into a structured resistance-training group and a control group, with all subjects receiving the appetite-suppressing medication.

Resistance Training Preserves Lean Tissue and Strength During Weight Loss

  • Preserving Lean Tissue: Combining resistance training with tirzepatide reduces muscle loss during substantial weight reduction.
  • Functional Strength: Patients who lift weights see measurable gains in upper- and lower-body strength, whereas medication-only users experience functional declines.
  • Body Composition: Targeted exercise shifts the ratio of weight lost away from muscle and toward fat mass.

Resistance Training Reduces Lean Soft Tissue Loss During Weight Loss

Researchers assigned 120 men and postmenopausal women aged 50 to 70 to either three weekly resistance-training sessions or their usual daily activities. Participants did not have type 2 diabetes. Both cohorts received general guidance regarding protein, fiber, and hydration intake.

Both study groups shed an average of 22 kilograms (roughly 49 pounds). However, body composition outcomes diverged notably between the two protocols. A reduction averaging 3.57 kg of lean soft tissue was recorded among individuals who did resistance training, contrasting with 4.67 kg for subjects taking only the medication, which amounts to a difference of roughly 1.1 kg.

Parallel reporting from The West Australian detailed that those who lifted weights lost 25 per cent less lean tissue, including muscle. The West Australian also reported that the training group increased their overall strength by 10 per cent, while strength in the non-exercising cohort declined by 10 per cent.

People taking weight-loss drugs such as Ozempic need to do this one thing, according to a landmark WA study
Photo: The West Australian
Metric (40-Week Trial) Tirzepatide + Resistance Training Tirzepatide Alone
Total Weight Loss ~22.0 kg to 22.28 kg ~22.0 kg to 22.61 kg
Fat Mass Loss 17.98 kg 17.19 kg
Strength Change +10% -10%

Pharmacology and Mechanisms of Action

Tirzepatide is the active ingredient in Mounjaro and Zepbound. Mounjaro is prescribed for type 2 diabetes in the United States, whereas Zepbound holds approval for weight management in qualified adults. The medication acts on two hormone receptors involved in appetite and food intake.

Lead investigator Prof. Danny Green said that therapy ought to focus on preserving physical performance as weight declines, and strongly advised clinicians to integrate resistance exercise into patient care plans.

“We now know that muscle loss can be reduced and strength increased when regular resistance training is used alongside tirzepatide treatment,” Green said in a university statement.

Lead investigator Prof. Danny Green emphasized the clinical imperative to maintain physical function during pharmacological weight reduction. “Loss of lean mass, including muscle, is an inevitable part of weight loss by any method – whether through diet and exercise alone, or medical or surgical interventions,” he said.

Prof. Danny Green said that the data validated the advantages of pairing strength training with anti-obesity drugs, further observing that such practices should theoretically extend healthspan—defined as the total years lived in good health, independence, and productivity, free from disabling chronic illnesses.

Eli Lilly Supplied Medication for the Investigator-Initiated Trial

According to university officials, the medication was provided by Eli Lilly, which played no part in the conception, execution, or assessment of the investigator-led trial. Several authors disclosed payments or advisory relationships with pharmaceutical or nutrition companies.

Zepbound’s US prescribing information already specifies use alongside a reduced-calorie diet and increased physical activity. The new trial provides evidence about one particular form of that activity: resistance training. The study tested a structured exercise program in a specific patient group. Its results cannot automatically be extended to other weight-loss drugs or exercise routines.

References

  • Nature Medicine: Resistance training preserves lean mass during tirzepatide treatment
  • The Jerusalem Post | JPost.com: Losing weight without losing as much muscle
  • The West Australian: WA study reveals lifting weights is crucial to preserving muscle when taking weight-loss drugs like Mounjaro
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

IRis Is an ESP32-powered Open Source Universal Infrared Remote

Denmark Secures 3-0 Victory Over Portugal in Braga